<- Go Home
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Market Cap
$33.5B
Volume
1.1M
Cash and Equivalents
$1.1B
EBITDA
$2.5B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$7.3B
Profit Margin
75.49%
52 Week High
$319.76
52 Week Low
$189.44
Dividend
N/A
Price / Book Value
2.20
Price / Earnings
28.71
Price / Tangible Book Value
47.74
Enterprise Value
$39.3B
Enterprise Value / EBITDA
14.72
Operating Income
$2.0B
Return on Equity
8.05%
Return on Assets
4.86
Cash and Short Term Investments
$1.1B
Debt
$6.9B
Equity
$15.2B
Revenue
$9.7B
Unlevered FCF
$1.1B
Sector
Biotechnology
Category
N/A